Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan List

Showing results (11-20 of 72) with videos related to

Pageof 8
Sort By:
Vitamins and Hormones|June 21, 2017
Erythropoietin Receptor Signaling and Lipid RaftsKathy McGraw, Alan List
Hemasphere|March 21, 2022
The role of innate immunity in MDS pathogenesisDavid A Sallman, Alan List
Current Hematologic Malignancy Reports|April 29, 2010
Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: Is it any good?Mikkael A Sekeres, Alan List
Blood|January 24, 2019
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromesDavid A Sallman, Alan List
Best Practice & Research. Clinical Haematology|September 26, 2006
Immunomodulation in myelodysplastic syndromesMikkael A Sekeres, Alan List
Current Hematology Reports|May 4, 2005
Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: is it any good?Mikkael A Sekeres, Alan List
Current Oncology Reports|August 20, 2022
New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric OncologyLodovico Balducci, Claire Falandry, Alan List
Seminars in Hematology|September 30, 2017
Lenalidomide: Myelodysplastic syndromes with del(5q) and beyondChetasi Talati, David Sallman, Alan List
Current Oncology Reports|November 3, 2022
Correction to: New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric OncologyLodovico Balducci, Claire Falandry, Alan List
Drugs & Aging|January 30, 2023
A Proactive Approach to Prevent Hematopoietic Exhaustion During Cancer Chemotherapy in Older Patients: Temporary Cell-Cycle ArrestLodovico Balducci, Claire Falandry, Alan List
Pageof 8

Showing results (11-20 of 72) with videos related to

Sort By:
Pageof 8
Vitamins and Hormones|June 21, 2017
Erythropoietin Receptor Signaling and Lipid RaftsKathy McGraw, Alan List
Hemasphere|March 21, 2022
The role of innate immunity in MDS pathogenesisDavid A Sallman, Alan List
Current Hematologic Malignancy Reports|April 29, 2010
Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: Is it any good?Mikkael A Sekeres, Alan List
Blood|January 24, 2019
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromesDavid A Sallman, Alan List
Best Practice & Research. Clinical Haematology|September 26, 2006
Immunomodulation in myelodysplastic syndromesMikkael A Sekeres, Alan List
Current Hematology Reports|May 4, 2005
Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: is it any good?Mikkael A Sekeres, Alan List
Current Oncology Reports|August 20, 2022
New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric OncologyLodovico Balducci, Claire Falandry, Alan List
Seminars in Hematology|September 30, 2017
Lenalidomide: Myelodysplastic syndromes with del(5q) and beyondChetasi Talati, David Sallman, Alan List
Current Oncology Reports|November 3, 2022
Correction to: New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric OncologyLodovico Balducci, Claire Falandry, Alan List
Drugs & Aging|January 30, 2023
A Proactive Approach to Prevent Hematopoietic Exhaustion During Cancer Chemotherapy in Older Patients: Temporary Cell-Cycle ArrestLodovico Balducci, Claire Falandry, Alan List
Pageof 8